Impact of COVID-19 on critically ill patients' - mortality prediction models based on serum FTIR-spectra

Rúben Araújo¹, Tiago AH Fonseca¹, Cristiana Von Rekowski¹, L. Bento^{2,3} and C.R.C. Calado¹

- 1) Health & Engineering Lab., ISEL Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, R. Conselheiro Emídio Navarro 1, 1959-007 Lisboa, Portugal.
- 2) Intensive Care Department, Centro Hospitalar Universitário de Lisboa Central, CHULC; Rua José António Serrano, 1150-199 Lisboa, Portugal.
- 3) Integrated Pathophysiological Mechanisms, CHRC, NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa; Campo Mártires da Pátria, 130, 1169-056 Lisboa, Portugal.

Abstract

Due to the relevance of mortality prediction of critically ill patients, it is common practice at intensive care units (ICU) to use physiological scores, e.g., APACHE II. However, these type of scorings don't enable to predict individual patients' outcome, mostly used for comparing groups of patients and ICUs [1]. It is therefore relevant to discover robust biomarkers of mortality prediction at ICU. Since FTIR spectroscopy can capture the whole molecular fingerprint of a system in a very specific and sensitive mode [2,3], in the present work, diverse mortality predictive models of support vector machines (SVM), based on FTIR-spectra of serum of critically ill patients, were developed. Serum samples from 200 patients at an ICU, with half presenting COVID-19 and the other half not presenting this infection, were considered. SVM models were optimized by combining spectral regions with diverse spectra preprocessing methods. A model cross-validation strategy, based on 10 random iterations, with 80% of samples for training and 20% for validation, was implemented. It was possible to develop very good SVM models to predict mortality based only on patients without COVID-19 (AUC=0.90), and a slightly better model was achiever for patients with COVID-19 (AUC=0.93). This difference can result from COVID-19 patients presenting a different metabolic status in relation to non-COVID-19 patients. Indeed, a very good SVM model enabled to discriminate these two populations (AUC=0.83). When considering the mixed population (i.e., with and without COVID-19), a slightly worse predictive SVM model was obtained (AUC=0.88).

Keywords

FTIR, COVID19, Mortality, ICU, Biomarkers

Acknowledgements: This research was funded by Fundação para a Ciência e a Tecnologia (FCT, Portugal), grant DSAIPA/DS/0117/2020- Predictive Models of COVID-19 Outcomes for Higher Risk Patients Towards a Precision Medicine. Serum samples from critically ill patients were obtained according to legal and ethics requirements, including project ethics approval by the Hospital Ethics Committee (Centro Hospitalar Universitário Lisboa Central), and patients informed consent.

References

- [1] W. A. Knaus, J. E. Zimmerman, D. P. Wagner, E. A. Draper, and D. E. Lawrence, "APACHE-acute physiology and chronic health evaluation: a physiologically based classification system.", Crit. Care Med., vol. 9, no. 8, pp. 591–597, 1981, doi: 10.1097/00003246-198108000-00008.
- [2] R. Araújo, L. Ramalhete, E. Ribeiro, and C. Calado, "Plasma versus Serum Analysis by FTIR Spectroscopy to Capture the Human Physiological State," BioTech, vol. 11, no. 4, p. 56, Dec. 2022, doi: 10.3390/biotech11040056.
- [3] R. Araújo, L. Ramalhete, H. Paz, C. Ladeira, CRC Calado. A new method to predict genotoxic effects based on serum molecular profile. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2021 Jul 5;255:119680. doi: 10.1016/j.saa.2021.119680.

Figure captions

- Fig.1. t-SNE of COVID-19 (red) and non-COVID19 (blue) patients.
- Fig.2. t-SNE of deceased (red) and discharged, i.e., survived (blue) patients.